FTC, GTCR and Surmodics
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
4d
Zacks Investment Research on MSNSRDX Stock Falls Following Plan for Legal Action Against FTC ChallengeSurmodics, Inc. SRDX recently provided a statement in response to the U.S. Federal Trade Commission (“FTC”) blocking the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results